Income Statement (TTM)
Avadel Pharmaceuticals plc Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33 | 22 | 10 | 0 | 0 | 1 | 9 | 28 | 55 | 95 | 138 | 169 | 194 | 221 |
| Change (%) | -32.99 | -54.82 | -100.00 | NaN | ∞ | 468.85 | 228.59 | 97.19 | 72.56 | 45.20 | 22.41 | 14.98 | 13.69 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | ||
| Cost Of Sales | 8 | 6 | 3 | 0 | 0 | 0 | 0 | 1 | 2 | 5 | 11 | 15 | 19 | 23 |
| Change (%) | -29.60 | -42.79 | -100.00 | NaN | ∞ | 325.00 | 452.94 | 179.91 | 116.22 | 117.93 | 36.92 | 26.54 | 18.51 | |
| % of Revenue | 24.47 | 25.71 | 32.55 | 2.41 | 1.80 | 3.03 | 4.29 | 5.38 | 8.08 | 9.03 | 9.94 | 10.36 | ||
| Gross Operating Profit | 25 | 17 | 7 | 0 | 0 | 1 | 8 | 27 | 53 | 90 | 127 | 154 | 175 | 198 |
| Change (%) | -34.09 | -58.98 | -100.00 | NaN | ∞ | 472.40 | 224.48 | 94.61 | 70.60 | 41.07 | 21.13 | 13.83 | 13.16 | |
| % of Revenue | 75.53 | 74.29 | 67.45 | 97.59 | 98.20 | 96.97 | 95.71 | 94.62 | 91.92 | 90.97 | 90.06 | 89.64 | ||
| SG&A | 31 | 32 | 36 | 44 | 56 | 102 | 127 | 152 | 176 | 171 | 178 | 181 | 178 | 185 |
| Change (%) | 4.22 | 9.56 | 22.76 | 29.51 | 81.29 | 24.49 | 19.09 | 15.92 | -2.77 | 3.94 | 1.87 | -1.68 | 3.77 | |
| % of Revenue | 93.29 | 145.09 | 351.84 | 6,839.77 | 1,496.89 | 542.52 | 318.93 | 179.71 | 128.64 | 107.05 | 91.54 | 83.55 | ||
| R&D | 23 | 20 | 19 | 21 | 20 | 17 | 17 | 13 | 12 | 12 | 13 | 15 | 16 | 17 |
| Change (%) | -10.78 | -8.21 | 14.42 | -5.54 | -15.08 | -0.49 | -22.62 | -5.75 | -1.38 | 7.74 | 14.42 | 8.46 | 1.24 | |
| % of Revenue | 68.75 | 91.53 | 185.95 | 1,151.14 | 201.37 | 47.42 | 22.67 | 12.96 | 9.61 | 8.99 | 8.48 | 7.55 | ||
| OpEx | 63 | 59 | 58 | 65 | 77 | 120 | 145 | 166 | 191 | 188 | 202 | 212 | 214 | 224 |
| Change (%) | -6.02 | -2.10 | 12.63 | 17.94 | 55.86 | 20.99 | 14.61 | 15.03 | -1.20 | 7.28 | 4.63 | 1.09 | 4.91 | |
| % of Revenue | 188.35 | 264.15 | 572.35 | 7,993.32 | 1,700.06 | 592.97 | 345.89 | 198.04 | 146.32 | 125.07 | 109.96 | 101.47 | ||
| Operating Income | -29 | -37 | -48 | -65 | -77 | -118 | -136 | -138 | -136 | -93 | -64 | -42 | -19 | -3 |
| Change (%) | 24.50 | 30.02 | 36.48 | 17.94 | 53.91 | 15.31 | 1.24 | -1.64 | -31.20 | -31.39 | -33.75 | -54.33 | -83.27 | |
| % of Revenue | -88.35 | -164.15 | -472.35 | -7,893.32 | -1,600.06 | -492.97 | -245.89 | -98.04 | -46.32 | -25.07 | -9.96 | -1.47 | ||
| Interest Expense | -13 | -13 | -12 | -10 | -9 | -12 | -11 | -10 | -9 | -10 | -10 | -11 | -10 | -10 |
| Change (%) | 0.92 | -9.70 | -11.14 | -12.76 | 36.03 | -12.82 | -8.35 | -6.75 | 4.57 | 8.73 | 3.32 | -3.27 | -3.45 | |
| % of Revenue | -38.63 | -58.18 | -116.27 | -827.07 | -126.76 | -35.35 | -16.72 | -10.13 | -7.59 | -6.40 | -5.39 | -4.58 | ||
| Net Income | 16 | 7 | -6 | -56 | -66 | -143 | -159 | -160 | -157 | -106 | -73 | -49 | -26 | -3 |
| Change (%) | -54.85 | -179.00 | 908.77 | 18.39 | 115.38 | 11.29 | 0.84 | -2.15 | -32.27 | -31.68 | -32.72 | -45.92 | -88.93 | |
| % of Revenue | 46.71 | 31.47 | -55.02 | -9,546.26 | -1,867.69 | -573.17 | -284.42 | -111.64 | -52.53 | -28.87 | -13.58 | -1.32 | ||
Source: Capital IQ
